Welcome to our dedicated page for 10x Genomics SEC filings (Ticker: TXG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
10x Genomics, Inc. filings document regulatory disclosures for a Nasdaq-listed life science technology company with Class A common stock. Form 8-K reports furnish quarterly and annual operating results, selected preliminary results and business updates related to single cell and spatial biology platforms, including instruments, consumables, software and product launches.
The filing record also includes definitive proxy materials covering board matters, executive compensation, equity awards and shareholder voting items, as well as Form 8-K disclosure for executive officer transitions and related compensation arrangements. These documents describe TXG's public-company governance, registered security, financial reporting events and material corporate updates.
10x Genomics, Inc. (TXG) reported that its Chief Executive Officer, Serge Saxonov, sold a total of 10,486 shares of Class A Common Stock on August 26, 2026. The sales, executed as open-market or private transactions, were carried out pursuant to a Rule 10b5-1 trading plan adopted on November 29, 2025 and occurred in multiple trades with weighted average prices between approximately $62.53 and $64.99. The filing also notes indirect holdings of Class A shares in three trusts—the Andromeda Trust, the Y/S Descendants' Trust, and the Y/S Pot Trust—for which Saxonov serves as trustee.
10x Genomics, Inc. (TXG) is the issuer in a notice that Serge Saxonov, its Director and CEO, intends to sell up to 35,486 shares of Class A common stock under Rule 144 through J.P. Morgan Securities LLC. The proposed sale has an aggregate market value of $2,206,653.92, with 120,212,296 shares of Class A common stock reported as outstanding. The shares to be sold were acquired via 10,486 RSUs vesting on August 21, 2026 as compensation and 25,000 shares from an option exercise on April 1, 2019 for cash. Over the prior three months, Saxonov sold 30,000 shares of Class A common stock on June 22, 2026 for proceeds of $1,033,268.67.
10x Genomics, Inc. (TXG) reported an insider transaction by Chief Executive Officer and director Serge Saxonov. On 2026-08-24, he sold 18,545 shares of Class A Common Stock at a weighted average price of $63.0237 per share in open-market trades, solely to cover tax withholding obligations arising from the vesting of restricted stock units. After this sale, he directly held 1,085,835 shares of Class A Common Stock and also had indirect holdings through three trusts for which he serves as trustee.
10x Genomics, Inc. (TXG) reported that its Chief Financial Officer, Adam Taich, sold 17,166 shares of Class A common stock on 2026-08-24. The filing states the shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units. The weighted average sale price was $63.023 per share, with individual trades executed between $63.0088 and $63.73. After these sales, Taich directly held 362,732 shares of Class A common stock.
10x Genomics, Inc. (TXG) reported that Benjamin J. Hindson, its President and Chief Scientific Officer and a director, sold 13,818 shares of Class A common stock on August 24, 2026. The shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units, and Hindson held 488,182 shares directly after the transaction. The sale price reflected a weighted average of $63.0236 per share from multiple trades between $63.0088 and $63.78.
10x Genomics, Inc. (TXG) director Shehnaaz Suliman reported two open-market sales of Class A Common Stock on August 24, 2026. The transactions totaled 2,207 shares, consisting of 561 shares at a weighted average price of $62.7259 and 1,646 shares at a weighted average price of $63.9664. Both sales were executed under a Rule 10b5-1 trading plan adopted on March 13, 2026, and each price reflects a weighted average across multiple trades within stated price ranges.
10x Genomics, Inc. (TXG) is the issuer for a planned resale of its common stock under Rule 144 by officer Adam Taich. The notice covers up to 16,614 shares of common stock, with an aggregate market value of $1,081,903.68, to be sold through Morgan Stanley Smith Barney LLC Executive Services, with an approximate sale date of August 24, 2026 on NASDAQ. These shares relate to a Restricted Stock Unit Grant acquired on August 21, 2026 in consideration for services rendered, covering 32,650 shares. Shares outstanding for 10x Genomics were 120,212,296, which is a baseline figure and not the amount being sold.
10x Genomics, Inc. (TXG) received a Rule 144 notice relating to proposed sales of its common stock by Serge Saxonov. The notice covers up to 17,948 shares of common stock, with an indicated aggregate market value of $1,168,773.76, to be sold through Morgan Stanley Smith Barney LLC on or after August 24, 2026. The filing states that 10x Genomics had 120,212,296 shares of common stock outstanding. The securities to be sold were acquired via a Restricted Stock Unit Grant of 35,271 shares from the issuer in exchange for services rendered, with acquisition dated August 21, 2026.
The notice also lists prior sales of 10x Genomics common stock by Serge Saxonov during the past three months, including transactions on May 26, 2026 and June 22, 2026 at stated share counts and dollar amounts.
10x Genomics, Inc. (TXG) is the issuer of common stock covered by a notice of proposed sale filed for the account of Benjamin J. Hindson. The filing contemplates the sale of 13,373 shares of TXG common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $870,849.76 and 120,212,296 shares of common stock outstanding. The shares relate to a Restricted Stock Unit Grant acquired on 08/21/2026, with services rendered as consideration.
10x Genomics, Inc. (TXG) is the issuer for a proposed sale of its Class A common stock under Rule 144 by stockholder Shehnaaz Suliman, with J.P. Morgan Securities LLC acting as agent and attorney-in-fact. The notice covers a planned sale of 2,207 Class A common shares, associated with RSU vesting, to be sold through J.P. Morgan Securities LLC. The filing states an aggregate market value for these securities of $143,719.84 and lists 120,212,296 shares of Class A common stock outstanding. It also notes that, in the past three months, Suliman sold 5,723 shares of Class A common stock for $186,756.21.